ADTX News and Press, ADiTx Therapeutics Inc. From 04/05/22

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security ...

Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO &a...

Aditxt meets the timeline imposed by the FDA for laboratory-developed tests (“LDT”s) to request Emergency Use Authorization (“EUA”) by January 14 th AditxtScore™ for COVID-19 will continue to be available during the FDA review A...

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month. The three-day event, in association with the London Stock Exchange, global...

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on...

NEW YORK, NY / ACCESSWIRE / December 31, 2021 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Aditxt Inc. (NASDAQ:ADTX) and AiPharma Global Holdings LLC is fair to Aditxt shareholders. Halper Sadeh encourages Aditxt shareholders to click her...

Aditxt (NASDAQ:ADTX) jumps 10% pre market as it signs an amendment to its February 3, 2020, exclusive license agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore and securing worldwide exclusivity in all fie...

The amendment expands AditxtScore’s clinical utility for personalizing the selection of the right treatment for individuals and monitoring their response to the treatment Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech in...

Confirming earlier reports, Aditxt (NASDAQ:ADTX) has announced a share exchange agreement to acquire AiPharma Global Holdings, a subsidiary of AiPharma Group. AiPharma owns exclusive rights to Avigan and all formulation of its active pharmaceutical ingredient Favipiravir. These oral antiviral...

If complete, the transaction would be the first step in establishing commercial presence in infectious disease therapeutics and transforming Aditxt into a global biotech company Aditxt Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the ...